Regeneron's Phase III trial investigated cemdisiran and pozelimab as both monotherapies and in combination in gMG.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results